Headlines about The Medicines (NASDAQ:MDCO) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. The Medicines earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.7555755435956 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news articles that may have effected Accern’s scoring:

Shares of The Medicines (NASDAQ MDCO) opened at 37.83 on Tuesday. The stock’s market capitalization is $2.72 billion. The company’s 50-day moving average is $37.27 and its 200 day moving average is $43.96. The Medicines has a 12 month low of $30.80 and a 12 month high of $55.95.

The Medicines (NASDAQ:MDCO) last announced its earnings results on Wednesday, August 9th. The company reported ($5.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.29) by $4.23. The firm had revenue of $18.74 million during the quarter, compared to the consensus estimate of $29.64 million. The Medicines had a negative return on equity of 137.20% and a negative net margin of 670.46%. The business’s revenue for the quarter was down 65.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.62) earnings per share. Equities research analysts predict that The Medicines will post ($9.69) earnings per share for the current year.

A number of analysts have recently weighed in on MDCO shares. Chardan Capital reaffirmed a “buy” rating and issued a $85.00 target price (up from $80.00) on shares of The Medicines in a research report on Tuesday, August 29th. ValuEngine raised shares of The Medicines from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Zacks Investment Research raised shares of The Medicines from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research report on Tuesday, August 8th. CIBC set a $50.00 target price on shares of The Medicines in a research report on Tuesday, May 23rd. Finally, Citigroup Inc. upped their target price on shares of The Medicines from $43.00 to $45.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. The Medicines presently has an average rating of “Buy” and a consensus price target of $54.00.

TRADEMARK VIOLATION WARNING: “The Medicines (MDCO) Receives Daily Media Impact Rating of 0.18” was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/05/the-medicines-mdco-receives-daily-media-impact-rating-of-0-18.html.

The Medicines Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Insider Buying and Selling by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.